Schroder Investment Management Group decreased its holdings in Catalent, Inc. (NYSE:CTLT) by 18.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,127,016 shares of the company’s stock after selling 903,527 shares during the quarter. Schroder Investment Management Group owned approximately 3.29% of Catalent worth $163,017,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of CTLT. Janus Henderson Group PLC acquired a new position in Catalent in the second quarter valued at $239,629,000. BlackRock Inc. lifted its holdings in Catalent by 15.2% in the second quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock valued at $614,695,000 after buying an additional 2,316,849 shares during the period. Eagle Asset Management Inc. lifted its holdings in Catalent by 290.9% in the third quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock valued at $47,636,000 after buying an additional 858,600 shares during the period. AJO LP acquired a new position in Catalent in the second quarter valued at $26,130,000. Finally, Macquarie Group Ltd. lifted its holdings in Catalent by 60.2% in the second quarter. Macquarie Group Ltd. now owns 1,786,764 shares of the company’s stock valued at $62,715,000 after buying an additional 671,429 shares during the period. 94.69% of the stock is currently owned by institutional investors.

In other news, Director Uwe Roehrhoff purchased 7,500 shares of the company’s stock in a transaction on Tuesday, November 21st. The stock was acquired at an average cost of $39.22 per share, for a total transaction of $294,150.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Christine Dolan sold 1,594 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total transaction of $61,767.50. The disclosure for this sale can be found here. 1.70% of the stock is owned by insiders.

Catalent, Inc. (NYSE CTLT) opened at $39.49 on Monday. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01. The stock has a market cap of $5,246.60, a PE ratio of 27.62, a price-to-earnings-growth ratio of 2.54 and a beta of 1.49. Catalent, Inc. has a twelve month low of $22.94 and a twelve month high of $43.39.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.01. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The firm had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $490.75 million. During the same period in the previous year, the company earned $0.16 earnings per share. The firm’s quarterly revenue was up 23.0% on a year-over-year basis. sell-side analysts predict that Catalent, Inc. will post 1.46 EPS for the current fiscal year.

Several equities analysts recently issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of Catalent in a report on Monday, October 23rd. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday, November 3rd. BidaskClub upgraded shares of Catalent from a “hold” rating to a “buy” rating in a report on Thursday, October 5th. ValuEngine upgraded shares of Catalent from a “hold” rating to a “buy” rating in a report on Thursday, September 7th. Finally, Piper Jaffray Companies upped their price objective on shares of Catalent from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, November 7th. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $42.11.

TRADEMARK VIOLATION NOTICE: “Schroder Investment Management Group Decreases Holdings in Catalent, Inc. (CTLT)” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/schroder-investment-management-group-decreases-holdings-in-catalent-inc-ctlt/1728766.html.

Catalent Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.